Nova Patents
LU88809I2

Substituted-1,3-oxathiolanes with antiviral properties

Abstract

Disclosed are compounds of the formula <CHEM> wherein R1 is hydrogen; R2 is a purine or pyrimidine base or an analogue or derivative thereof; Z is S, S=O or SO2; and pharmaceutically acceptable derivatives thereof. Also described are use of the compounds as antiviral agents, pharmaceutical formulations, and methods for the preparation of the compounds.

Term

Term ended

Projected expiry passed 8 February 2010, 16.6 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

153 members in 45 offices

This recordMember, by publication datePriority claim35 more offices are in the list below

Priority claims2

Priority claims
DocumentOfficeKindDate
30810189United States of AmericaA
2152269CanadaA

Members153

Family members, oldest first
DocumentOfficeKind
DK172089D0DenmarkD0
IE891136LIrelandL
AU3264489AAustraliaA
DK172089ADenmarkA
EP0337713A2European Patent Office (EPO)A2
KR890016046ARepublic of KoreaA
IL89921A0IsraelA0
IL89921D0IsraelD0
JPH01316375AJapanA
ZA892645BSouth AfricaB
FI900631A0FinlandA0
NO900619D0NorwayD0
HU900708D0HungaryD0
AP9000163A0African Regional Intellectual Property Organization (ARIPO)A0
CA2009637A1CanadaA1
IE900452LIrelandL
IE960758LIrelandL
NO900619LNorwayL
AU4920190AAustraliaA
EP0382526A2European Patent Office (EPO)A2
CN1044817AChinaA
PT93094APortugalA
KR900012932ARepublic of KoreaA
HUT53362AHungaryA
ZA90943BSouth AfricaB
EP0337713A3European Patent Office (EPO)A3
JPH037282AJapanA
AP136AAfrican Regional Intellectual Property Organization (ARIPO)A
US5041449AUnited States of AmericaA
US5047407AUnited States of AmericaA
NZ228645ANew ZealandA
YU24390AYugoslavia, later Serbia and Montenegro (until 2006)A
EP0382526A3European Patent Office (EPO)A3
OA09193AAfrican Intellectual Property Organization (OAPI)A
CS410991A3Czechoslovakia (until 1993)A3
US5151426AUnited States of AmericaA
AU630913B2AustraliaB2
OA09470AAfrican Intellectual Property Organization (OAPI)A
AU631786B2AustraliaB2
MX19437AMexicoA
IL89921AIsraelA
HU208134BHungaryB
NZ232421ANew ZealandA
US5270315AUnited States of AmericaA
CA2152269A1CanadaA1
WO9414802A1World Intellectual Property Organization (WIPO)A1
AU3154993AAustraliaA
MY105523AMalaysiaA
PL164785B1PolandB1
HU210537A9HungaryA9
IL93318AIsraelA
HU9501825D0HungaryD0
EP0674634A1European Patent Office (EPO)A1
EP0337713B1European Patent Office (EPO)B1
US5466806AUnited States of AmericaA
AT129247TAustriaT
ATE129247T1AustriaT1
DE68924549D1GermanyD1
ES2078234T3SpainT3
PT93094BPortugalB
HK5996AHong Kong, ChinaA
GR3017812T3GreeceT3
DE68924549T2GermanyT2
LV5730A4LatviaA4
JPH08504212AJapanA
JPH08119967AJapanA
EP0382526B1European Patent Office (EPO)B1
EP0711771A2European Patent Office (EPO)A2
KR960007531B1Republic of KoreaB1
AT138065TAustriaT
ATE138065T1AustriaT1
DE69026971D1GermanyD1
ES2086371T3SpainT3
EP0711771A3European Patent Office (EPO)A3
NO179518BNorwayB
DK0382526T3DenmarkT3
LV5730B4LatviaB4
GR3019919T3GreeceT3
DE69026971T2GermanyT2
HUT73655AHungaryA
SI9010243ASloveniaA
CN1033640CChinaC
FI98065BFinlandB
LU88809I2This recordLuxembourgI2
NL960025I1Netherlands (Kingdom of the)I1
IE71225B1IrelandB1
NL960025I2Netherlands (Kingdom of the)I2
IE72184B1IrelandB1
FI98065CFinlandC
HRP940040A2CroatiaA2
HK51997AHong Kong, ChinaA
JP2644357B2JapanB2
CZ282720B6CzechiaB6
CA2009637CCanadaC
RU2092485C1Russian FederationC1
US5684164AUnited States of AmericaA
CA1339609CCanadaC
CY2036ACyprusA
KR0137023B1Republic of KoreaB1
SG48737A1SingaporeA1
Showing 100 of 153